Ukusebenzisa i-Gaviscon for Heartburn

Indlela I-Antacid Ikuvikela Ngayo I-Reflux Acid

I-Gaviscon iyi-anti-the-counter (OTC) engahlosile enezithako ezidala isivinini se-foam esivikela ukuhlangana kwesisu nesisu. Funda ukuthi kusebenza kanjani ukuvimbela noma ukukhulula uphawu lokuphuza nokuphuza nokuthi yiziphi izinyathelo okufanele uziphathe nale mithi.

Sibutsetelo

Ngaphandle kwezithako ezithinta i-acid ezitholakala ezinhlobonhlobo eziningi (i-aluminium hydroxide ne-magnesium carbonate), i-Gaviscon iqukethe i-alginic acid ne-sodium bicarbonate.

Inhlanganisela ye-alginic acid kanye ne-bicarbonate idala isivinini se-foam esihamba ngesisu esiswini. Lesi sivinini se-gel sidlulisa ipokhethi ye-asidi ekhona ekuhlanganiseni kwesisu nesisu futhi ingasiza ukunciphisa inani lama-reflux episodes. Kungase futhi inikeze isinyathelo eside esingapheli ekubhebhethekeni kwesifo kubantu abane- reflux isifo se-gastroesophageal (GERD) .

Izinzuzo

Ucwaningo oluthile luye lwathola ukuthi i-Gaviscon inganciphisa izimpawu zokuphuza izinhliziyo kulabo abane-acid reflux. Izifo ezincane, zingasetshenziswa zodwa. Kulabo abane-reflux enamandla, kubonakala sengathi i-Gavison ingase ibe yengezo eliwusizo kubantu abanempendulo engenele ku- proton pump inhibitors . Ngaphandle kokunciphisa izimpawu kanye nenani lama-reflux episodes, i-Gaviscon ibonakala inciphisa i-postprandial (ngemuva kokudla) amazinga e-asidi kulesisindo njengoba kulinganiswa iphenyo ye-pH.

Izithako kanye nemininingwane yomkhiqizo

Amathebulethi avamile Amandla (kuthebhulethi ngayinye)

Amathebulethi engeziwe engeziwe (kuthebhulethi ngayinye)

Isikhathi Esiqinile Somandla (ku-isipuni ngasinye)

I-Power Strength Liquid (ku-isipuni ngasinye)

Ukusetshenziswa

I-Gaviscon ifika njengethebhulethi ehlaziywayo kanye ne-liquid ukuze ithathe ngomlomo. Ukuze imithi yokusebenza kahle udinga ukuhlaziya kahle amaphilisi futhi akufanele ukugwinya. Phuza ingilazi yamanzi emva kokuthatha amaphilisi. Hlanganisa kahle amanzi omlomo ngaphambi kokusetshenziswa komunye ukuxuba imithi ngokulinganayo. I-liquid ingase ixubane namanzi noma ubisi.

Landela izinkomba zelebula yephakheji noma kwilebuli yakho yesigceme ngokucophelela, bese ubuza udokotela noma ummithi wakho ukuthi achaze noma iyiphi ingxenye ongayiqondi. Thatha i-aluminium hydroxide ne-magnesium antacids ngokuqondile njengoba kuqondiswe. Ungathathi okungaphezulu noma uthathe isikhathi esiningi kunokuba umiswe udokotela wakho. Ungathathi ama-antacids ngamasonto angaphezu kweyodwa kuya kwamabili ngaphandle kokubekwa udokotela wakho.

Ukuqapha okukhethekile

Thatha lezi zinyathelo zokuthola imiphumela emihle futhi unciphise imiphumela emibi:

Okuqhamuka uma udla imishanguzo

Imiphumela emibi evela ku-Gaviscon ayijwayelekile. Eqinisweni, isifundo se-2016 esibheka umphumela we-Gaviscon wokuguquka kwenhliziyo awutholanga umehluko emiphumeleni emibi phakathi kwalabo abasebenzisa i-Gaviscon nalabo abathatha i-placebo. Noma kunjalo, kunemiphumela emibi engenzeka. Tshela udokotela wakho ukuthi noma iyiphi yalezi zimpawu zinzima noma awuhambi:

Imithombo:

> Reimer C, uLødrup AB, Smith G, Wilkinson J, Bytzer P. Isivivinyo Somtholampilo Esihleliwe: i-Alginate (i-Gaviscon Advance) ne-Placebo njenge-Add-on Therapy ku-Reflux Iziguli ezinezimpendulo ezingenele kwi-Once Proton Pump Inhibitor. I-Pharmaceutical Pharmacy & Therapeutics edingekayo 43, cha. 8 (2016): 899-909. i-doi: 10.1111 / apt.13567.

> Thomas E., Wade A., Crawford G., Jenner B., Levinson N., u-Wilkinson J. Randomized Clinical Trial: Ukukhululeka Kwezimpawu Zokugaya Emathunjini Ngama-Acid Pocket-Targeting Alginate-Antacid (i-Gaviscon Double Action) - I-Double -Blind, Placebo-Controlled, Pilot Study in Gastro-Oesophageal Reflux Izifo. I-Pharmacy ejwayelekile kanye Nezokwelapha . 2014. 39 (6): 595-602.

> Yuan YZ, Fang JY, Zou DW, Levinson N, Jenner B, Wilkinson J. Alginate-Antacid (I-Gaviscon Double Action) Amathebulethi ahlawulekayo Nciphisa Ukubonakala Kwama-Acid Acid in Iziguli ZaseShayina ezinezifo ze-Reflux nezifo ze-Heartburn Izimpawu zesifo se-gastroesophageal. I-Journal of Digestive Diseases . 2016; 17 (11): 725-734. i-doi: 10.1111 / 1751-2980.12406.